# Immune-Onc Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immune-onc-therapeutics

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.immune-onc.com
- Total disclosed funding: $138M
- Latest round: Series B (Jan 5, 2023)
- Investors on record: 11

## About

Based in California, US, and founded in 2016, Immune-Onc Therapeutics, Inc. operates as a clinical-stage cancer immunotherapy company. The company was founded by Charlene Liao. In March 2021, Immune-Onc Therapeutics, Inc. raised its latest series B funding from Oceanpine Capital.

Immune-Onc Therapeutics, Inc. is a developer of immunotherapies approaches such as Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB), LAIR1, IO-202, IO-106, and IO-108.

Immune-Onc Therapeutics, Inc. plans to use its funding from March to advance its portfolio of blood cancer and solid tumor immunotherapies targeting myeloid checkpoints.

## Funding rounds

- Series B, Jan 5, 2023, $25M — Triwise Capital, Proxima Ventures
- Series B, Jan 26, 2021, $73M — Vivo Capital, NLVC, The Leukemia & Lymphoma Society, Oceanpine Capital, Octagon Capital Advisors
- Series B, Mar 18, 2018, $33M — Vivo Capital, NLVC, Stanford-StartX Fund, Loyal Valley Capital
- Series A, Jul 1, 2016, $7M — Fame Mount Limited, CLI Ventures

## Investors

- Fame Mount Limited — Series A
- CLI Ventures (https://capitalatlas.ai/funds/cli-ventures) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- Stanford-StartX Fund — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- The Leukemia & Lymphoma Society — Series B
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series B
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series B
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series B
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series B